louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03309969: Comparison of Intravascular Ultrasound With Venography in the Diagnosis and Treatment of Iliac Vein Compression Syndrome
Official title: Comparison of Intravascular Ultrasound With Venography in the Diagnosis and Treatment of Iliac Vein Compression Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Iliac Vein Compression Syndrome
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2017-10-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with suspicious iliac vein compression syndrome

Brief summary: The aim of this study is to compare intravascular ultrasound with venography in the diagnosis and treatment of iliac vein compression syndrome.


Eligibility criteria: Inclusion Criteria:

* Age: 18 to 90 years
* Willing to participate in and sign the informed consent
* Patients with suspicious iliac vein stenosis or compression presented by preoperative magnetic resonance venography (MRV)
* Patent common femoral vein and/or femoral vein of the study leg
* Undergoing iliofemoral venography with the intend to treat potential iliac vein compression syndrome

Exclusion Criteria:

* Not providing informed consent
* Venous compression caused by pelvic tumors or fibroid uterus
* Previous stent implantation or venovenous bypass surgery of the study leg
* Known metal allergy precluding the possibility of stent implantation
* Known iodine allergy or severe renal insufficient function which are unsuitable for venography
* Pregnant or planning to be pregnant recently
* Acute deep vein thrombosis or tumor thrombus involving the study leg
* Know history of thrombophilia (e.g. protein C or S deficiency, anti-thrombin III deficiency, etc )
* Any concurrent disease, for example, heart failure, might make the patients unsuitable for surgery

Primary outcomes:
measure: Percentage diameter reduction
timeFrame: 1 month
measure: Percentage area reduction
timeFrame: 1 month
Secondary outcomes:
measure: CEAP score
timeFrame: 18 months
measure: Primary patency
timeFrame: 18 months
measure: Secondary patency
timeFrame: 18 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: 180 Fenglin Road
state: Shanghai
Study officials:
References:
Clinical trial NCT00002169: A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
Official title: A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cytomegalovirus Retinitis
HIV Infections
Keywords: AIDS-Related Opportunistic Infections
Placebos
Antiviral Agents
Cytomegalovirus Retinitis
Treatment Outcome
Nelfinavir
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.


Eligibility criteria: Inclusion Criteria

Patients must have:

* HIV infection.
* Newly diagnosed or first progression of CMV retinitis.

Exclusion Criteria

Prior Medication:

Excluded:

Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Univ of Southern California / LA County USC Med Cntr
state: California
city: Orange
country: United States
facility: Univ of California / UCI Med Ctr
state: California
city: San Diego
country: United States
facility: Univ of California / San Diego Treatment Ctr
state: California
city: Torrance
country: United States
facility: Harbor UCLA Med Ctr
state: California
city: Washington
country: United States
facility: George Washington Univ
state: District of Columbia
city: Chicago
country: United States
facility: Northwestern Univ / SOCA
state: Illinois
city: Galveston
country: United States
facility: Univ of Texas Med Branch
state: Texas
city: Houston
country: United States
facility: Baylor Univ
state: Texas
Study officials:
References:
Clinical trial NCT02600169: Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
Official title: Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Melanoma
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
First posted: 2015-11-09
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.

Brief summary: This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.

Detailed description: This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.

Eligibility criteria: All patients that were eligible for treatment with pembrolizumab in the Named Patient Program in the Netherlands.

Primary outcomes:
measure: Early serum response markers
timeFrame: up to day 126
measure: Predicitve patient characteristics
timeFrame: baseline
measure: Predictive tumor characteristics
timeFrame: baseline
measure: Adverse events of clinical interest will be collected and graded according to the CTCAE version 4.0 criteria
timeFrame: 2 years
Secondary outcomes:
measure: Survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
Study officials:
affiliation: University Medical Center Groningen
name: G.A.P. Hospers, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01601769: Tissue Sparing Therapy of Female Precancerous Genital Lesions With VITOM
Official title: Development of a Tissue Sparing Procedure for the Diagnosis and Therapy of Female Precancerous Genital Lesions Combining Endoscopic and Ultrasound Technics.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cervical Preinvasive Disease
Keywords: Cervical preinvasive disease
Colposcopy
Exocolposcopy
Leep
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2012-05-18
Enrollment: 300
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Object of the study is the evaluation of the use of a rigid laparoscope for the diagnosis and therapy of lesions of the female genital tract as a substitution or a complementary method to colposcopy with the development of new standards for a tissue sparing therapy Use of existing laparoscopic instruments, which allow a better quality level in the diagnosis and therapy than the current routine.

Development of new optics and instruments, which allow a tissue sparing approach Pre and postoperative measurement of the cervical volume, to be sure that the tissue removal is kept to a minimum level Development of qualitaty parameters for the most tissue respecting operations of the uterine cervix Prospective evaluation of the influence of tissue sparing surgery on future pregnancies


Eligibility criteria: Inclusion Criteria:

* Karnowsky-Index \> 80,
* 18-80 years,
* CIN.

Exclusion Criteria:

* Pregnancy,
* Previous or current cancer,
* Radio therapy of the pelvis,
* Serious internistic accompanying diseases,
* Psychiatric diseases,
* HIV infection,
* Drug addiction.

Primary outcomes:
measure: Cervical volume removed
timeFrame: İmmediately after surgery
measure: İntraoperative Complications
timeFrame: During the intraoperative
measure: Short term complications
timeFrame: Within 48 hours after operation
measure: Late complications
timeFrame: After 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité University Hospital
Study officials:
affiliation: Charité University Hospital, Berlin, Germany
name: Achim Schneider, MD, MPH
role: STUDY_DIRECTOR
References:
Clinical trial NCT03126669: Oxygen as a Limiting Factor for Performing Multitasking
Official title: Oxygen as a Limiting Factor for Performing Multitasking: Functional Evaluation Under Normobaric and Hyperbaric Oxygenation of Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Change
Keywords: Hyperbaric oxygen
multitasking performance
cognitive funcitons
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2017-04-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of the present study was to evaluate whether hyperbaric oxygen (HBO) environment, with increased oxygen supply to the brain, will enable better performance of complex and/or multiple activities.

Detailed description: The Brain uses 20% of the total oxygen supply consumed by the entire body. Even though, less than 10% of the brain is active at every given time, the brain utilizes almost all the oxygen delivered. In order to perform different tasks or more than one task (multi-tasking), the oxygen supply is shifted from one brain region to another, via modulation of blood perfusion.

The aim of the present study was to evaluate whether hyperbaric oxygen (HBO) environment, with increased oxygen supply to the brain, will enable better performance of complex and/or multiple activities.

Methods: a prospective, double blind randomized control, cross over trial including healthy volunteers. Participants were asked to perform a cognitive task, a motor task and a simultaneous cognitive-motor task (multi-tasking). Participants were randomized to perform the tasks at 2 environments: (a) normobaric air (1ATA 21% oxygen) (b) HBO (2ATA 100% oxygen). Two weeks later participants were crossed to the alternative environment. Blinding of the normobaric environment was achieved in the same chamber with masks on while hyperbaric sensation was simulated by increasing pressure in the first minute and gradually decreasing to normobaric environment prior to tasks performance.

Eligibility criteria: Inclusion Criteria:

* healthy volunteers,
* minimum of 12 years of formal education

Exclusion Criteria:

* any inner ear pathologies,
* any lung disease,
* any mental or physical limitation of participat in going into oxygen chamber environment

Primary outcomes:
measure: Cognitive/Attention Symbol-Digit Modality Test (SDMT)
timeFrame: 45 minutes
measure: Motor task: transferring of beans
timeFrame: 45 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: Assaf-Harofeh Medical Center
Study officials:
affiliation: Asaf-Harofhe MC
name: Shai a Efrati, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06466369: Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia
Official title: Efficacy and Safety of Once Daily Administration Tadalafil in Patients With Benign Prostatic Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: BPH With Other Lower Urinary Tract Symptoms
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-06-20
Enrollment: 306
Sex: MALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel, double-blinded, prospective, randomized controlled study.
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.


Eligibility criteria: Inclusion Criteria:

* Aged ≥ 45 years and sexually active with symptomatic benign prostatic hyperplasia (no hospitalization 3 months prior to start of treatment).

Exclusion Criteria:

* 1. Patients with bladder or prostate malignancy. 2. A history of lower urinary tract surgery. 3. History of catheterization. 4. Urinary retention. 5. Urinary tract infection. 6. Stone disease. 7. Any neurological disease.

Primary outcomes:
measure: Evaluation of International prostate symptom score (IPSS)/quality of life (QoL).
timeFrame: 3 months compared to baseline
measure: Evaluation of International index of erectile function (IIEF).
timeFrame: 3 months compared to baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: outpatient clinic of the urology department at AlZahraa University Hospital, Al-Azhar University, Faculty of Medicine for Girls.
Study officials:
References:
Clinical trial NCT00773669: Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Official title: Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: male breast cancer
Male breast cancer patients diagnosed and/or
treated at Summa Health System/Akron City Hospital
from the reference year of 1995 through 2007.
Lead sponsor: Summa Health System
Sponsor class: OTHER
First posted: 2008-10-16
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Males with breast cancer.

Brief summary: The primary goal of this retrospective study is to evaluate the male breast cancer patient population at Summa Health System/Akron City Hospital over a period of 18 years and compare the findings to historical data.

The objectives are to:

* identify risk factors.
* evaluate stage and histology at the time of presentation.
* document treatment modalities and outcomes.
* analyze outcomes for comparison to historical data.


Eligibility criteria: Inclusion Criteria:

* Male breast cancer patients diagnosed and/or treated at Summa Health System/Akron City Hospital from the reference year of 1995 through 2007.

Primary outcomes:
measure: Retrospective chart review to evaluate the male breast cancer patient population at Summa Health System/Akron City Hospital over a period of years and compare the findings to historical data.
timeFrame: Chart review from 1995-2007
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Summa Health System
name: Gary Williams, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002069: A Study of DTC in Patients With AIDS and AIDS Related Complex
Official title: A Study of DTC in Patients With AIDS and AIDS Related Complex
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Ditiocarb
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.


Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

* Active opportunistic infection or progressive Kaposi's sarcoma (KS).
* Dementia.
* Lymphoma.

Concurrent Medication:

Excluded within 3 weeks of study entry:

* Other experimental AIDS therapy.

Patients with the following are excluded:

* Active opportunistic infection or progressive Kaposi's sarcoma (KS).

Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Univ of Arizona / Arizona Cancer Ctr
state: Arizona
city: Los Angeles
country: United States
facility: USC School of Medicine / Norris Cancer Hosp
state: California
city: San Francisco
country: United States
facility: San Francisco AIDS Clinic / San Francisco Gen Hosp
state: California
city: Sherman Oaks
country: United States
facility: Portion Med Group
state: California
city: Key West
country: United States
facility: Florida Keys Memorial Hosp
state: Florida
city: Brooklyn
country: United States
facility: SUNY / Health Sciences Ctr at Brooklyn
state: New York
city: Durham
country: United States
facility: Duke Univ Med Ctr
state: North Carolina
city: Houston
country: United States
facility: Dr Gary Brewton
state: Texas
Study officials:
References:
citation: Hersh EM, et al. A randomized, double-blind, placebo-controlled trial of diethyldithiocarbamate (Ditiocarb, Imuthiol(R) in patients with ARC and AIDS. Int Conf AIDS. 1990 Jun 20-23;6(3):208 (abstract no SB489)
Clinical trial NCT04942769: Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis
Official title: Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Selenium
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
First posted: 2021-06-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: patients with Autoimmune thyroiditis
Primary purpose: TREATMENT

Brief summary: To evaluate the effects of exogenous selenium supplementation on autoimmune thyroiditis.

Detailed description: In patients with autoimmune thyroiditis， investigators compared changes in thyroid function, anti-thyroid peroxidase antibody, anti-thyroglobulin antibody, thyroid magnetic resonance T1-mapping values and metabolic indicatorsfrom baseline to the end of treatment (12 weeks)

Eligibility criteria: Inclusion Criteria:

* Men or women between the ages of 18 and 75
* Clinical diagnosis of autoimmune thyroiditis, serum TPOAb and TGAB positive
* Thyroid function is normal, and no drugs affecting thyroid function such as Umetole and Serge have been used

Exclusion Criteria:

* The contraindications indicated in the Chinese instructions of the drug
* Hypothyroidism, hyperthyroidism
* Liver function impairment
* Renal function impairment
* Claustrophobia
* Mental disorders

Primary outcomes:
measure: anti-thyroglobulin antibody changes
timeFrame: Changes from baseline and 3 months during follow-up
measure: T1-mapping values of Thyroid MRI
timeFrame: Changes from baseline and 3 months during follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Chao-Yang Hospital, Capital Medical University
state: Beijing
Study officials:
affiliation: Beijing Chao Yang Hospital
name: Guang Wang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04266769: Precision Orthodontics: A Comparison of Custom vs Traditional Bracket Treatment Efficiency
Official title: Precision Orthodontics: A Comparison of Custom vs Traditional Bracket Treatment Efficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Malocclusion
Lead sponsor: LightForce Orthodontics
Sponsor class: INDUSTRY
First posted: 2020-02-12
Enrollment: 14
Sex: ALL
Minimum age (years): 10
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This investigational testing aims to target multiple investigations sites to examine treatment efficiency metrics using a completely digital and patient-specific bracket treatment system for the correction of malocclusions.


Eligibility criteria: Inclusion Criteria:

* All subjects must be healthy and between the ages of 10 and 65.
* Eruption of all permanent teeth excluding second and third molars
* Sufficient labial tooth surface for bonding
* No more than one tooth missing from a single arch quadrant
* No existing molar tubes or bands

Exclusion Criteria:

* Presence of systemic diseases, cleft lip and palate, craniofacial anomalies, syndromes affecting bone or teeth, impacted teeth (excluding 3rd molars), and tumors of the parathyroid gland
* Presence of bridges or implants
* Cases requiring orthognathic surgery
* Significant periodontal disease
* Intake of drugs affecting tooth movement or bone formation (chronic use of Non-Steroidal Anti-Inflammatory Drugs, bisphosphonates, levothyroxine, or teriparatide drug class)
* Pregnancy

Primary outcomes:
measure: Length of Bonding Appointment
timeFrame: 1 day
measure: Number of Debonded Brackets
timeFrame: approximately 2 years
measure: Length of Treatment
timeFrame: approximately 2 years
measure: Length of Debond Appointment
timeFrame: 1 day
measure: Length of Time to Achieve Leveling and Aligning
timeFrame: 2 years
measure: Number of Unscheduled Appointments
timeFrame: 2 years
measure: Number of Repositioned Brackets
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Maple
country: Canada
facility: Walt Orthodontics
state: Ontario
Study officials:
affiliation: LightForce Orthodontics
name: Kelsey Fafara, BS
role: STUDY_DIRECTOR
References: